JP2017532289A - 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用 - Google Patents

突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用 Download PDF

Info

Publication number
JP2017532289A
JP2017532289A JP2017500952A JP2017500952A JP2017532289A JP 2017532289 A JP2017532289 A JP 2017532289A JP 2017500952 A JP2017500952 A JP 2017500952A JP 2017500952 A JP2017500952 A JP 2017500952A JP 2017532289 A JP2017532289 A JP 2017532289A
Authority
JP
Japan
Prior art keywords
antibody
product
amino acid
group
product according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017500952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532289A5 (enExample
Inventor
バルクホルン，シュテファン
ヒレン，ハインツ
シュトリービンガー・アンドレーアス
ギアイジ，ジモーネ
Original Assignee
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー filed Critical アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー
Publication of JP2017532289A publication Critical patent/JP2017532289A/ja
Publication of JP2017532289A5 publication Critical patent/JP2017532289A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
JP2017500952A 2014-07-07 2015-07-06 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用 Pending JP2017532289A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462021308P 2014-07-07 2014-07-07
US62/021,308 2014-07-07
PCT/EP2015/065362 WO2016005328A2 (en) 2014-07-07 2015-07-06 IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020156999A Division JP2021001203A (ja) 2014-07-07 2020-09-18 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用

Publications (2)

Publication Number Publication Date
JP2017532289A true JP2017532289A (ja) 2017-11-02
JP2017532289A5 JP2017532289A5 (enExample) 2018-08-16

Family

ID=53525183

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017500952A Pending JP2017532289A (ja) 2014-07-07 2015-07-06 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用
JP2020156999A Pending JP2021001203A (ja) 2014-07-07 2020-09-18 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用
JP2022192713A Pending JP2023036606A (ja) 2014-07-07 2022-12-01 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020156999A Pending JP2021001203A (ja) 2014-07-07 2020-09-18 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用
JP2022192713A Pending JP2023036606A (ja) 2014-07-07 2022-12-01 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用

Country Status (11)

Country Link
US (2) US20160000891A1 (enExample)
EP (1) EP3166969A2 (enExample)
JP (3) JP2017532289A (enExample)
CN (1) CN107074924A (enExample)
AU (2) AU2015286824A1 (enExample)
CA (1) CA2954031A1 (enExample)
IL (1) IL249925B (enExample)
MX (1) MX2017000094A (enExample)
RU (1) RU2750268C2 (enExample)
SG (1) SG11201700071WA (enExample)
WO (1) WO2016005328A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018058837A (ja) * 2010-04-15 2018-04-12 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
MX2017000094A (es) * 2014-07-07 2017-04-27 Abbvie Deutschland PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS.
CN117054645A (zh) 2016-09-06 2023-11-14 富士瑞必欧株式会社 甲状腺球蛋白的测定方法及测定试剂
CN109564214A (zh) * 2016-09-13 2019-04-02 富士瑞必欧株式会社 心肌肌钙蛋白的测定方法及测定试剂
CA3100035A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
CN110412294B9 (zh) * 2019-08-07 2023-05-26 深圳市新产业生物医学工程股份有限公司 蛋白稳定液、蛋白校准品、试剂盒及检测蛋白校准品稳定性的方法
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
CN112851786B (zh) * 2019-11-12 2022-11-15 深圳市新产业生物医学工程股份有限公司 可溶性的Aβ1-42变体、Aβ1-42校准品及试剂盒
CN111793131A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中pf4含量的抗体对及其用途
KR102711715B1 (ko) * 2021-01-28 2024-09-30 주식회사 에이브레인 신경 퇴행성 질환의 치료를 위한 유전자 요법
EP4230645A1 (en) * 2022-02-22 2023-08-23 Technische Universität München Peptidic inhibitors of amyloid self- and cross-assembly
CN117700525B (zh) * 2024-02-05 2024-06-18 上海良润生物医药科技有限公司 一种多肽改造体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529084A (ja) * 2008-07-25 2011-12-01 アボット・ラボラトリーズ アミロイドβペプチド類似体、これらのオリゴマー、前記類似体またはオリゴマーを調製するためのプロセスおよび前記類似体またはオリゴマーを含む組成物ならびにこれらの使用
JP2013523182A (ja) * 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
JP2013537424A (ja) * 2010-08-14 2013-10-03 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CN117903302A (zh) * 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
MX2017000094A (es) * 2014-07-07 2017-04-27 Abbvie Deutschland PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529084A (ja) * 2008-07-25 2011-12-01 アボット・ラボラトリーズ アミロイドβペプチド類似体、これらのオリゴマー、前記類似体またはオリゴマーを調製するためのプロセスおよび前記類似体またはオリゴマーを含む組成物ならびにこれらの使用
JP2013523182A (ja) * 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
JP2013537424A (ja) * 2010-08-14 2013-10-03 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018058837A (ja) * 2010-04-15 2018-04-12 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
JP2020103288A (ja) * 2010-04-15 2020-07-09 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質

Also Published As

Publication number Publication date
US20160000891A1 (en) 2016-01-07
IL249925B (en) 2021-09-30
RU2017103527A3 (enExample) 2019-02-19
IL249925A0 (en) 2017-03-30
JP2023036606A (ja) 2023-03-14
WO2016005328A3 (en) 2016-05-26
RU2017103527A (ru) 2018-08-07
US20240075114A1 (en) 2024-03-07
AU2021200575A1 (en) 2021-03-04
CA2954031A1 (en) 2016-01-14
MX2017000094A (es) 2017-04-27
BR112017000428A2 (pt) 2017-10-31
CN107074924A (zh) 2017-08-18
JP2021001203A (ja) 2021-01-07
SG11201700071WA (en) 2017-02-27
AU2015286824A1 (en) 2017-02-09
WO2016005328A2 (en) 2016-01-14
RU2750268C2 (ru) 2021-06-25
EP3166969A2 (en) 2017-05-17

Similar Documents

Publication Publication Date Title
JP2023036606A (ja) 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用
JP7061875B2 (ja) アミロイドベータタンパク質に対するモノクローナル抗体及びその使用
CN104744591B (zh) β淀粉样蛋白结合蛋白
CN105348387B (zh) β淀粉样蛋白结合蛋白
CN101652146A (zh) 新的Aβ构象异构体选择性抗Aβ球聚体的单克隆抗体
US20100173828A1 (en) Aß(X - 38 .. 43) oligomers, and processes, compositions, and uses thereof
RU2742493C2 (ru) Вещества и способы для применения при предупреждении и/или лечении болезни гентингтона
BR112017000428B1 (pt) Produto imunogênico com base em sequências de aminoácidos muteína amiloide beta, composição compreendendo o produto e uso do mesmo para tratar ou prevenir amiloidose
MX2008007006A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200519